In this online CME self-learning activity:
Bipolar disorder is a mood disorder characterized by episodes of mania, hypomania, and depression. It affects 3-4% of the U.S. population, represents a substantial societal and economic burden in the United States, is also found to be strongly associated with other major public health concerns like diabetes and cardiovascular disease as well as suicide.
The literature demonstrates that medication nonadherence is a major issue among patients with bipolar disorder. Nonadherence affects approximately 60% of patients and can result in hospitalization, poor effectiveness, increased relapses, and increased risk of morbidity. Other factors, such as patient perceptions, illness severity, and the relationship between the physician and patient, come into play and should be taken into account to optimize adherence.
Healthcare professionals specializing in: family medicine, internal medicine, mental health, neurology and psychiatry, or those who otherwise commonly care for patients with bipolar or related psychiatric diseases.
This program is supported by an educational grant from Alkermes.
Learners may participate in this activity free of charge.
Release Date: September 11, 2020 -- Expiration Date: September 11, 2022
Faculty: Rimal Bera, MD
Bipolar disorder’s epidemiology, neuropathophysiology, presentation, comorbidities, and psychosocial impact:
o Diagnostic criteria
Treatment with an emphasis on bipolar disorder I
o Prescription medications
o Acute treatment of mania
o Mixed episodes
o Maintenance treatment
o Treatment follow-up and assessment of outcomes
o Best practice: Putting it all together
o Patient case(s)
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
ACCME Activity #201861271ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Remal Bera, MD, Clinical Professor, Department of Psychiatry & Human Behavior, University of California, Irvine, has no relevant conflicts of interest to disclose.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, CEO of ScientiaCME, has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Alkermes.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Improving the treatment and management of schizophrenia: An overview of current and novel approaches
Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents: Updates from APA 2019
Attention Deficit Hyperactivity Disorder (ADHD) in Adults: Updates from APA 2019
Opioid dependence and opioid use disorder: Best practices, barriers in care, and the role of long-acting injectable medication